Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 January 2007, Vol. 109, No. 1, pp. 259-270.
Prepublished online as a Blood First Edition Paper on September 19, 2006; DOI 10.1182/blood-2006-03-012948.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
blood-2006-03-012948v1
109/1/259    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stamatopoulos, K.
Right arrow Articles by Davi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stamatopoulos, K.
Right arrow Articles by Davi, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 29, 2006
Accepted August 16, 2006

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations

Kostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, Myriam Boudjograh, Giuseppe Guida, Tatjana Smilevska, Lynda Belhoul, Stefania Stella, Niki Stavroyianni, Marta Crespo, Anastasia Hadzidimitriou, Laurent Sutton, Francesc Bosch, Nikolaos Laoutaris, Achilles Anagnostopoulos, Emili Montserrat, Athanasios Fassas, Guillaume Dighiero, Federico Caligaris-Cappio, Helene Merle-Beral, Paolo Ghia*, and Fred Davi

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
Hematology Department, Nikea General Hospital, Athens, Greece
Hospital Clinic, University of Barcelona, Barcelona, Spain
Laborary of Hematology & Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France
Institute for Cancer Research and Treatment, IRCC, Torino, Italy
Department of Clinical Hematology, Hopital Victor Dupouy, Argenteuil, France
Unite d'Immuno-Hematologie et d'Hematopathologie, Institut Pasteur, Paris, France
Universita Vita-Salute, San Raffaele and Istituto Scientifico San Raffaele, Milano, Italy
Universita Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milano, Italy

* Corresponding author; email: ghia.paolo{at}hsr.it.

Chronic lymphocytic leukemia (CLL) immunoglobulin repertoire is biased and characterized by the existence of subsets of cases with closely homologous ("stereotyped") complementarity-determining region 3 (CDR3) sequences. In the present series, 201/916 CLL patients (21.9%) expressed IGHV genes which belonged to one of 48 different subsets of sequences with stereotyped heavy chain (H) CDR3. Twenty-six subsets comprised ≥3 sequences and were considered "confirmed". The remaining subsets comprised pairs of sequences and were considered "potential"; public-database CLL sequences were found to be members of 9/22 "potential" subsets, thereby allowing to consider them also "confirmed". The chance of belonging to a subset exceeded 35% for unmutated and/or selected IGHV genes (e.g, IGHV1-69/3-21/4-39). Comparison to non-CLL public-database sequences showed that HCDR3 restriction is "CLL-related". CLL cases with selected stereotyped IGs were also found to share unique biological and clinical features. In particular, cases expressing stereotyped IGHV4-39/IGKV1-39-1D-39 and IGHV4-34/IGKV2-30 were always IgG-switched. In addition, IGHV4-34/IGKV2-30 patients were younger and followed a strikingly indolent disease, contrasting other patients (e.g., those expressing IGHV3-21/IGLV3-21) who experienced an aggressive disease, regardless of IGHV mutations. These findings suggest that a particular antigen binding site can be critical in determining the clinical features and outcome for at least some CLL patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-Cappio, and P. Ghia
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
Blood, July 1, 2008; 112(1): 188 - 195.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. M. Ghia, S. Jain, G. F. Widhopf II, L. Z. Rassenti, M. J. Keating, W. G. Wierda, J. G. Gribben, J. R. Brown, K. R. Rai, J. C. Byrd, et al.
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection
Blood, May 15, 2008; 111(10): 5101 - 5108.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
F. Forconi, E. Sozzi, D. Rossi, S. S. Sahota, T. Amato, D. Raspadori, L. Trentin, L. Leoncini, G. Gaidano, and F. Lauria
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia
Haematologica, May 1, 2008; 93(5): 697 - 705.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Lanemo Myhrinder, E. Hellqvist, E. Sidorova, A. Soderberg, H. Baxendale, C. Dahle, K. Willander, G. Tobin, E. Backman, O. Soderberg, et al.
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
Blood, April 1, 2008; 111(7): 3838 - 3848.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. F. Widhopf II, C. J. Goldberg, T. L. Toy, L. Z. Rassenti, W. G. Wierda, J. C. Byrd, M. J. Keating, J. G. Gribben, K. R. Rai, and T. J. Kipps
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3
Blood, March 15, 2008; 111(6): 3137 - 3144.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. Athanasiadou, K. Stamatopoulos, M. Gaitatzi, N. Stavroyianni, A. Fassas, and A. Anagnostopoulos
Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins
Haematologica, March 1, 2008; 93(3): 473 - 474.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Murray, N. Darzentas, A. Hadzidimitriou, G. Tobin, M. Boudjogra, C. Scielzo, N. Laoutaris, K. Karlsson, F. Baran-Marzsak, A. Tsaftaris, et al.
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis
Blood, February 1, 2008; 111(3): 1524 - 1533.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. W. Hauswirth and U. Jager
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
Haematologica, January 1, 2008; 93(1): 14 - 19.
[Full Text] [PDF]


Home page
BloodHome page
R. Bomben, M. Dal Bo, D. Capello, D. Benedetti, D. Marconi, A. Zucchetto, F. Forconi, R. Maffei, E. M. Ghia, L. Laurenti, et al.
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study
Blood, April 1, 2007; 109(7): 2989 - 2998.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020